Revised SPC: Keytruda (pembrolizumab) 50 mg powder for concentrate for solution for infusion

Myelitis has been added as a rare adverse effect following monotherapy and gastrointestinal ulceration has been added as an uncommon adverse effect following monotherapy, and in combination with chemotherapy and axitinib.

electronic Medicines compendium